forzinity vs SS-31: Mechanism & Clinical Research Comparison
Disclaimer: All content on this site is based on public academic research and clinical data for educational and informational reference only. It is not medical advice. No treatment or health-related decisions should be made based solely on website content. This site does not sell pharmaceuticals or endorse any medical treatment.
Same molecule: what is actually being compared
Chemically, there is nothing to compare: forzinity and ss-31 are the same tetrapeptide (elamipretide, D-Arg–2',6'-Dmt–Lys–Phe–NH2 — see our structure page). The comparison that matters is between two channels for the same substance: a regulated prescription product with an FDA label, GMP manufacturing and specialty distribution; and a research-grade catalog chemical sold for laboratory use with a certificate of analysis and no regulatory standing whatsoever. The name map is on the forzinity and elamipretide page.
This page exists because the comparison is the most common real question in this topic space — and the most commonly mangled. SEO pages blur the channels to convert pharmaceutical search traffic toward research-grade sellers; pharmacy pages ignore the research channel entirely. We compare the channels honestly and recommend neither: no purchase guidance, no channel preference, full stop (see our disclaimer).
The parameter comparison
The measurable differences are stark and quantifiable. Documentation: an FDA-approved label, GMP audit trail and lot-level regulatory controls vs a certificate of analysis and research-use-only terms. Legal status: a lawful prescription drug within its channel vs a laboratory reagent whose sale for any non-research purpose sits outside its terms. Price: list-price data around $59,636 per 14 mL supply (the cost pillar documents the drivers) vs catalog prices roughly £30–94 per 10 mg documented on the elamipretide cost page.
The price ratio — roughly three orders of magnitude per milligram — is not primarily a chemistry cost. It is the accumulated cost structure of clinical development, regulatory compliance, orphan-population economics and specialty distribution. The research channel prices the synthesis; the regulated channel prices the entire evidence structure behind the label. Neither number is “wrong”; they price different things.
What the clinical record does and does not connect
The evidence asymmetry is the part comparison content usually omits. The clinical record — TAZPOWER's approval, the nulls in heart failure and AMD documented on their respective pages, the safety data on the safety overview — belongs entirely to the regulated product. Nothing in the research-channel record substitutes for it: a COA documents chemical identity and purity, not clinical outcomes in any population.
The research channel's legitimate record is the basic-science literature — decades of mechanism work summarized on the mechanism page — which is real, peer-reviewed, and the scientific foundation both channels rest on. Keeping which literature belongs to which question straight is most of the analytical work in this comparison.
Using the comparison without misusing it
The legitimate use of this comparison is analytical: understanding orphan-drug economics, channel structure, documentation standards, and why the same molecule can be a $59,636 drug and a £5-per-mg reagent simultaneously. The illegitimate use — treating research-grade material as a budget version of the drug — is a category error with legal and safety dimensions, and nothing on this site supports it.
The table below is therefore structured for analysis, not acquisition: every parameter row documents what differs between channels, with sources. The data-usage steps operationalize the analytical reading; anyone arriving at this page shopping rather than researching has missed what it documents.
How to use the data on this page
Step 1 — extract the parameters. Extract the comparison parameters in pairs — legal status, documentation, price basis, intended use, evidence base — and record each with its source document. A comparison row without two sources is an opinion, not a comparison.
Step 2 — normalize before comparing. Normalize prices to per-milligram of peptide with collection dates before quoting any ratio: the $59,636 supply figure and the £30–94/10 mg catalog band price different objects (approved product supply vs laboratory reagent). State the ratio as a channel comparison, never as a value judgment.
Step 3 — grade the source. Grade the source: regulatory documents for the approved channel; catalogs and their terms for the research channel; primary literature for the shared science. Any source that compares the channels while selling in one of them should be read with that interest visible.
Parameter comparison
forzinity (regulated product) vs ss-31 (research-grade channel), parameter by parameter.
| Parameter | forzinity (regulated) | ss-31 (research-grade) |
|---|---|---|
| Chemical identity | elamipretide tetrapeptide | Same molecule (elamipretide) |
| Regulatory status | FDA-approved drug (accelerated, 2025) | Laboratory reagent; no regulatory standing |
| Documentation | FDA label, GMP manufacturing, lot controls | Certificate of analysis, research-use-only terms |
| Documented indication research | Barth syndrome (label) | None — basic-science use only |
| Price basis (published data) | ≈$59,636 / 14 mL supply (list) | ≈£30–94 / 10 mg (catalog band) |
| Per-mg ballpark | Order of magnitude: hundreds of $/mg | Order of magnitude: a few $/mg |
| Supply channel | Specialty pharmacy (AnovoRx), prescription | Chemical suppliers, laboratory customers |
| Intended use | Prescribed pharmaceutical use | Laboratory research only |
| Clinical evidence | TAZPOWER program + safety label | None in this channel |
Table: forzinity (regulated product) vs ss-31 (research-grade channel), parameter by parameter. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
Is forzinity the same as ss-31?
Chemically yes — both are elamipretide. Commercially and legally they are entirely different objects: forzinity is an FDA-approved prescription drug; ss-31 in market usage refers to research-grade catalog material with no regulatory standing. This page compares the two channels parameter by parameter.
Why is forzinity so much more expensive than research-grade ss-31?
The regulated price carries the full cost structure: clinical development, regulatory approval, orphan-population economics, GMP manufacturing and specialty distribution. The research channel prices peptide synthesis alone. The roughly three-orders-of-magnitude per-milligram gap prices different things — documented in the cost pillar and the elamipretide cost page.
References
- FDA forzinity prescribing information and approval record, accessdata.fda.gov.
- drugs.com forzinity price data (2025–2026).
- Research-catalog public price listings for ss-31/elamipretide (collected 2025–2026).